Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemosubaiabimab + Anlotinib + Chemoradiotherapy in Oligometastatic Esophageal Cancer
NCT07455019Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2025
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bemosubaiabimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jiangsu Provincial People's Hospital. Started May 2025; status: recruiting.
02
Drugs
bemosubaiabimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07455019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455019.